ID,Description,GeneRatio,BgRatio,pvalue,p.adjust,qvalue,geneID,Count
R-HSA-381426,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),10/112,125/11091,4.938176067795715e-7,2.483902562101245e-4,2.2403725107578455e-4,7425/348/718/56975/6696/3486/3481/8542/1114/7018,10
R-HSA-8957275,Post-translational protein phosphorylation,9/112,108/11091,1.341760534326249e-6,3.3745277438305163e-4,3.0436778436558593e-4,7425/348/718/56975/6696/3486/8542/1114/7018,9
R-HSA-5578768,Physiological factors,3/112,14/11091,3.364834874048269e-4,0.04680035398491699,0.04221189194830851,4881/1482/25937,3
R-HSA-112315,Transmission across Chemical Synapses,10/112,270/11091,3.944883033957963e-4,0.04680035398491699,0.04221189194830851,7277/43/1103/57576/2901/2571/2902/4128/6572/1741,10
R-HSA-5083635,Defective B3GALTL causes PpS,4/112,37/11091,5.033798096193465e-4,0.04680035398491699,0.04221189194830851,170691/81794/170690/54437,4
R-HSA-5173214,O-glycosylation of TSR domain-containing proteins,4/112,38/11091,5.58254719501992e-4,0.04680035398491699,0.04221189194830851,170691/81794/170690/54437,4
R-HSA-9609736,Assembly and cell surface presentation of NMDA receptors,4/112,41/11091,7.482901254832488e-4,0.048373015784279855,0.04363036476514517,7277/57576/2902/1741,4
R-HSA-6785807,Interleukin-4 and Interleukin-13 signaling,6/112,108/11091,7.693521397102163e-4,0.048373015784279855,0.04363036476514517,4128/6097/2308/7124/4692/1052,6
R-HSA-373752,Netrin-1 signaling,4/112,44/11091,9.800363007029175e-4,0.054773139917063056,0.04940299948572602,9423/57453/137970/22885,4
R-HSA-112310,Neurotransmitter release cycle,4/112,51/11091,0.0017090519421136552,0.08596531268831685,0.07753698811063003,1103/2571/4128/6572,4
R-HSA-1368108,"BMAL1:CLOCK,NPAS2 activates circadian gene expression",3/112,27/11091,0.0024576264195585915,0.10170252414107882,0.09173127112023641,5054/79365/56938,3
R-HSA-2022854,Keratan sulfate biosynthesis,3/112,28/11091,0.0027324592003360043,0.10170252414107882,0.09173127112023641,4060/8534/9331,3
R-HSA-8878159,Transcriptional regulation by RUNX3,5/112,96/11091,0.002830132996603362,0.10170252414107882,0.09173127112023641,51176/6097/6696/1029/25937,5
R-HSA-112316,Neuronal System,11/112,410/11091,0.0028306865566105435,0.10170252414107882,0.09173127112023641,7277/43/1103/57576/2901/50944/2571/2902/4128/6572/1741,11
R-HSA-1474244,Extracellular matrix organization,9/112,300/11091,0.0033055709300363286,0.11084681185388488,0.09997902251548474,5054/4060/1756/4327/6696/170690/1293/3914/3679,9
R-HSA-112311,Neurotransmitter clearance,2/112,10/11091,0.004313805979606169,0.11420233724957385,0.10300556106428027,43/4128,2
R-HSA-1855167,Synthesis of pyrophosphates in the cytosol,2/112,10/11091,0.004313805979606169,0.11420233724957385,0.10300556106428027,55190/170685,2
R-HSA-193697,p75NTR regulates axonogenesis,2/112,10/11091,0.004313805979606169,0.11420233724957385,0.10300556106428027,4804/84894,2
R-HSA-70635,Urea cycle,2/112,10/11091,0.004313805979606169,0.11420233724957385,0.10300556106428027,445/1373,2
R-HSA-3906995,Diseases associated with O-glycosylation of proteins,4/112,69/11091,0.005146591348514178,0.12284534108424079,0.11080117611658004,170691/81794/170690/54437,4
R-HSA-400253,Circadian Clock,4/112,70/11091,0.005416726282380895,0.12284534108424079,0.11080117611658004,5054/79365/56938/8204,4
R-HSA-5173105,O-linked glycosylation,5/112,112/11091,0.005471040249072632,0.12284534108424079,0.11080117611658004,170691/81794/170690/9331/54437,5
R-HSA-1638074,Keratan sulfate/keratin metabolism,3/112,36/11091,0.005617182594309221,0.12284534108424079,0.11080117611658004,4060/8534/9331,3
R-HSA-451306,Ionotropic activity of kainate receptors,2/112,12/11091,0.006244054295904937,0.12563037243360733,0.11331315374884325,2901/1741,2
R-HSA-451308,Activation of Ca-permeable Kainate Receptor,2/112,12/11091,0.006244054295904937,0.12563037243360733,0.11331315374884325,2901/1741,2
R-HSA-3000178,ECM proteoglycans,4/112,76/11091,0.007238281430286466,0.1400329061320805,0.12630361524103104,5054/4060/1293/3679,4
R-HSA-193775,Synthesis of bile acids and bile salts via 24-hydroxycholesterol,2/112,14/11091,0.008496650465619008,0.14126802864998542,0.12741764224786797,8644/1645,2
R-HSA-418885,DCC mediated attractive signaling,2/112,14/11091,0.008496650465619008,0.14126802864998542,0.12741764224786797,9423/22885,2
R-HSA-9825892,Regulation of MITF-M-dependent genes involved in cell cycle and proliferation,2/112,14/11091,0.008496650465619008,0.14126802864998542,0.12741764224786797,51176/1029,2
R-HSA-1630316,Glycosaminoglycan metabolism,5/112,126/11091,0.008915994691095186,0.14126802864998542,0.12741764224786797,4060/8534/166012/9331/51363,5
R-HSA-193807,Synthesis of bile acids and bile salts via 27-hydroxycholesterol,2/112,15/11091,0.009739593934762631,0.14126802864998542,0.12741764224786797,8644/1645,2
R-HSA-2032785,YAP1- and WWTR1 (TAZ)-stimulated gene expression,2/112,15/11091,0.009739593934762631,0.14126802864998542,0.12741764224786797,1482/25937,2
R-HSA-2162123,Synthesis of Prostaglandins (PG) and Thromboxanes (TX),2/112,15/11091,0.009739593934762631,0.14126802864998542,0.12741764224786797,5730/8644,2
R-HSA-114608,Platelet degranulation,5/112,129/11091,0.009813007504606154,0.14126802864998542,0.12741764224786797,5054/7277/3481/7018/7424,5
R-HSA-975634,Retinoid metabolism and transport,3/112,44/11091,0.00982978330566499,0.14126802864998542,0.12741764224786797,348/8644/1645,3
R-HSA-216083,Integrin cell surface interactions,4/112,85/11091,0.010662665518487751,0.14898113210553718,0.13437452744059122,4060/6696/1293/3679,4
R-HSA-76005,Response to elevated platelet cytosolic Ca2+,5/112,134/11091,0.011442943172261804,0.15556217339588346,0.14031034160013764,5054/7277/3481/7018/7424,5
R-HSA-977606,Regulation of Complement cascade,3/112,47/11091,0.011775529293901413,0.15587082196927396,0.14058872924297808,718/3426/716,3
R-HSA-264642,Acetylcholine Neurotransmitter Release Cycle,2/112,17/11091,0.012450523681148068,0.15680734190443163,0.14143342965535216,1103/6572,2
R-HSA-6806667,Metabolism of fat-soluble vitamins,3/112,48/11091,0.012469768739915042,0.15680734190443163,0.14143342965535216,348/8644/1645,3
R-HSA-1474228,Degradation of the extracellular matrix,5/112,140/11091,0.01363167153116322,0.1666521078533763,0.1503129820755576,4327/6696/170690/1293/3914,5
R-HSA-190840,Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,2/112,18/11091,0.013915285347598023,0.1666521078533763,0.1503129820755576,7277/2697,2
R-HSA-442755,Activation of NMDA receptors and postsynaptic events,4/112,93/11091,0.014464284101900331,0.16919848612222946,0.15260970496741844,7277/57576/2902/1741,4
R-HSA-3781865,Diseases of glycosylation,5/112,144/11091,0.015238214045387933,0.17270563650091947,0.15577300268263322,170691/81794/4060/170690/54437,5
R-HSA-190872,Transport of connexons to the plasma membrane,2/112,19/11091,0.015450802470261185,0.17270563650091947,0.15577300268263322,7277/2697,2
R-HSA-2022870,Chondroitin sulfate biosynthesis,2/112,20/11091,0.017055523263824708,0.18649843916747452,0.16821351319698968,166012/51363,2
R-HSA-6794361,Neurexins and neuroligins,3/112,55/11091,0.01797963236182821,0.19224782750841313,0.17339921242257206,50944/2902/1741,3
R-HSA-442982,Ras activation upon Ca2+ influx through NMDA receptor,2/112,21/11091,0.01872791957835436,0.19224782750841313,0.17339921242257206,2902/1741,2
R-HSA-8849932,Synaptic adhesion-like molecules,2/112,21/11091,0.01872791957835436,0.19224782750841313,0.17339921242257206,2902/1741,2
R-HSA-438066,"Unblocking of NMDA receptors, glutamate binding and activation",2/112,22/11091,0.020466486587171654,0.19639037857678687,0.17713561403493802,2902/1741,2
R-HSA-9617324,Negative regulation of NMDA receptor-mediated neuronal transmission,2/112,22/11091,0.020466486587171654,0.19639037857678687,0.17713561403493802,2902/1741,2
R-HSA-166658,Complement cascade,3/112,58/11091,0.020693220804313527,0.19639037857678687,0.17713561403493802,718/3426/716,3
R-HSA-186797,Signaling by PDGF,3/112,58/11091,0.020693220804313527,0.19639037857678687,0.17713561403493802,6696/1293/56034,3
R-HSA-166663,Initial triggering of complement,2/112,23/11091,0.0222697424785363,0.20743852716118072,0.18710056546294626,718/716,2
R-HSA-193368,Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol,2/112,24/11091,0.02413622815109029,0.216795049285686,0.1955397431037578,8644/1645,2
R-HSA-9620244,Long-term potentiation,2/112,24/11091,0.02413622815109029,0.216795049285686,0.1955397431037578,2902/1741,2
R-HSA-9733709,Cardiogenesis,2/112,27/11091,0.030100807206115927,0.2656264214855493,0.23958352550020248,51176/1482,2
R-HSA-1483191,Synthesis of PC,2/112,28/11091,0.03220606474502206,0.2699941761124349,0.24352305096674567,43/1103,2
R-HSA-3295583,TRP channels,2/112,28/11091,0.03220606474502206,0.2699941761124349,0.24352305096674567,8989/80036,2
R-HSA-9619665,EGR2 and SOX10-mediated initiation of Schwann cell myelination,2/112,28/11091,0.03220606474502206,0.2699941761124349,0.24352305096674567,7402/25937,2
R-HSA-442742,CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling,2/112,29/11091,0.034367586812447,0.27882090591388453,0.25148437888225217,2902/1741,2
R-HSA-9615017,"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",2/112,29/11091,0.034367586812447,0.27882090591388453,0.25148437888225217,84676/2308,2
R-HSA-3000157,Laminin interactions,2/112,30/11091,0.036584044378860654,0.29209165591376046,0.2634540205060809,3914/3679,2
R-HSA-5668914,Diseases of metabolism,6/112,250/11091,0.04091567020020595,0.3138152449522691,0.28304775677394156,170691/81794/4060/4128/170690/54437,6
R-HSA-1251985,Nuclear signaling by ERBB4,2/112,32/11091,0.04117655301560588,0.3138152449522691,0.28304775677394156,348/6387,2
R-HSA-451326,Activation of kainate receptors upon glutamate binding,2/112,32/11091,0.04117655301560588,0.3138152449522691,0.28304775677394156,2901/1741,2
R-HSA-420092,Glucagon-type ligand receptors,2/112,33/11091,0.04355004832736154,0.32695036281586354,0.29489506408629734,7434/7432,2
R-HSA-5576891,Cardiac conduction,4/112,132/11091,0.04454269281674986,0.3294849189238997,0.2971811239012258,30818/4881/1482/25937,4
R-HSA-192105,Synthesis of bile acids and bile salts,2/112,34/11091,0.04597336707909195,0.3351391831997573,0.3022810253407876,8644/1645,2
R-HSA-438064,Post NMDA receptor activation events,3/112,80/11091,0.04705020650306626,0.3380893410148904,0.3049419398920535,7277/2902/1741,3
R-HSA-449147,Signaling by Interleukins,9/112,473/11091,0.0496283437548481,0.3418024553484813,0.30829100817242944,4128/6097/6850/2308/3600/90865/7124/4692/1052,9
R-HSA-9856651,MITF-M-dependent gene expression,3/112,82/11091,0.04999673024334789,0.3418024553484813,0.30829100817242944,51176/2766/1029,3
R-HSA-76002,"Platelet activation, signaling and aggregation",6/112,263/11091,0.05017187664013818,0.3418024553484813,0.30829100817242944,5054/7277/6850/3481/7018/7424,6
R-HSA-190861,Gap junction assembly,2/112,36/11091,0.05096458081736798,0.3418024553484813,0.30829100817242944,7277/2697,2
R-HSA-2173796,SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription,2/112,36/11091,0.05096458081736798,0.3418024553484813,0.30829100817242944,5054/25937,2
R-HSA-8964043,Plasma lipoprotein clearance,2/112,37/11091,0.053530076836241856,0.3542845874819691,0.3195493506429396,348/7436,2
R-HSA-8853884,Transcriptional Regulation by VENTX,2/112,38/11091,0.05614059784404833,0.35540360277608696,0.32055865396357325,51176/1029,2
R-HSA-6794362,Protein-protein interactions at synapses,3/112,86/11091,0.05615321225559179,0.35540360277608696,0.32055865396357325,50944/2902/1741,3
R-HSA-112314,Neurotransmitter receptors and postsynaptic signal transmission,5/112,205/11091,0.0565254239007693,0.35540360277608696,0.32055865396357325,7277/57576/2901/2902/1741,5
R-HSA-397014,Muscle contraction,5/112,205/11091,0.0565254239007693,0.35540360277608696,0.32055865396357325,1756/30818/4881/1482/25937,5
R-HSA-9031628,NGF-stimulated transcription,2/112,39/11091,0.05879499127706567,0.36510963718967937,0.3293130765486069,7425/429,2
R-HSA-2173782,Binding and Uptake of Ligands by Scavenger Receptors,2/112,42/11091,0.0670101537363327,0.4110500893826262,0.37074937433067257,348/8542,2
R-HSA-5362517,Signaling by Retinoic Acid,2/112,43/11091,0.06982887384715789,0.4231798017484387,0.3816898494372232,8644/1382,2
R-HSA-451927,Interleukin-2 family signaling,2/112,44/11091,0.07268597339675274,0.4352505311734123,0.3925771244862209,6850/3600,2
R-HSA-194068,Bile acid and bile salt metabolism,2/112,45/11091,0.07558040606826079,0.4357145465301746,0.392995646237324,8644/1645,2
R-HSA-190828,Gap junction trafficking,2/112,47/11091,0.08147716967366964,0.4357145465301746,0.392995646237324,7277/2697,2
R-HSA-69231,Cyclin D associated events in G1,2/112,47/11091,0.08147716967366964,0.4357145465301746,0.392995646237324,1028/1029,2
R-HSA-69236,G1 Phase,2/112,47/11091,0.08147716967366964,0.4357145465301746,0.392995646237324,1028/1029,2
R-HSA-9024446,NR1H2 and NR1H3-mediated signaling,2/112,47/11091,0.08147716967366964,0.4357145465301746,0.392995646237324,348/8204,2
R-HSA-5668541,TNFR2 non-canonical NF-kB pathway,3/112,102/11091,0.08411296115744385,0.4357145465301746,0.392995646237324,7293/7124/4050,3
R-HSA-157858,Gap junction trafficking and regulation,2/112,49/11091,0.08751112759693178,0.4357145465301746,0.392995646237324,7277/2697,2
R-HSA-2187338,Visual phototransduction,3/112,104/11091,0.08796046441038556,0.4357145465301746,0.392995646237324,348/8644/1645,3
R-HSA-1483249,Inositol phosphate metabolism,2/112,50/11091,0.09057711391759841,0.4357145465301746,0.392995646237324,55190/170685,2
R-HSA-1793185,Chondroitin sulfate/dermatan sulfate metabolism,2/112,50/11091,0.09057711391759841,0.4357145465301746,0.392995646237324,166012/51363,2
R-HSA-2173793,Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,2/112,51/11091,0.09367450198981224,0.4357145465301746,0.392995646237324,5054/25937,2
R-HSA-190377,FGFR2b ligand binding and activation,1/112,10/11091,0.09655272552491945,0.4357145465301746,0.392995646237324,2246,1
R-HSA-209968,Thyroxine biosynthesis,1/112,10/11091,0.09655272552491945,0.4357145465301746,0.392995646237324,1735,1
R-HSA-418890,Role of second messengers in netrin-1 signaling,1/112,10/11091,0.09655272552491945,0.4357145465301746,0.392995646237324,9423,1
R-HSA-428542,Regulation of commissural axon pathfinding by SLIT and ROBO,1/112,10/11091,0.09655272552491945,0.4357145465301746,0.392995646237324,9423,1
R-HSA-8963888,Chylomicron assembly,1/112,10/11091,0.09655272552491945,0.4357145465301746,0.392995646237324,348,1
R-HSA-8963901,Chylomicron remodeling,1/112,10/11091,0.09655272552491945,0.4357145465301746,0.392995646237324,348,1
R-HSA-8964058,HDL remodeling,1/112,10/11091,0.09655272552491945,0.4357145465301746,0.392995646237324,348,1
R-HSA-9617629,Regulation of FOXO transcriptional activity by acetylation,1/112,10/11091,0.09655272552491945,0.4357145465301746,0.392995646237324,2308,1
R-HSA-9757110,Prednisone ADME,1/112,10/11091,0.09655272552491945,0.4357145465301746,0.392995646237324,1645,1
R-HSA-2428928,IRS-related events triggered by IGF1R,2/112,52/11091,0.09680235893382337,0.4357145465301746,0.392995646237324,3481/2246,2
R-HSA-383280,Nuclear Receptor transcription pathway,2/112,52/11091,0.09680235893382337,0.4357145465301746,0.392995646237324,6097/8013,2
R-HSA-2428924,IGF1R signaling cascade,2/112,53/11091,0.09995976720314491,0.4357145465301746,0.392995646237324,3481/2246,2
R-HSA-2404192,Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R),2/112,54/11091,0.10314582437462719,0.4357145465301746,0.392995646237324,3481/2246,2
R-HSA-5620924,Intraflagellar transport,2/112,54/11091,0.10314582437462719,0.4357145465301746,0.392995646237324,7277/57576,2
R-HSA-1839122,Signaling by activated point mutants of FGFR1,1/112,11/11091,0.1056842204027475,0.4357145465301746,0.392995646237324,2246,1
R-HSA-193692,Regulated proteolysis of p75NTR,1/112,11/11091,0.1056842204027475,0.4357145465301746,0.392995646237324,4804,1
R-HSA-196025,Formation of annular gap junctions,1/112,11/11091,0.1056842204027475,0.4357145465301746,0.392995646237324,2697,1
R-HSA-446107,Type I hemidesmosome assembly,1/112,11/11091,0.1056842204027475,0.4357145465301746,0.392995646237324,3914,1
R-HSA-9614399,Regulation of localization of FOXO transcription factors,1/112,11/11091,0.1056842204027475,0.4357145465301746,0.392995646237324,2308,1
R-HSA-9690406,Transcriptional regulation of testis differentiation,1/112,11/11091,0.1056842204027475,0.4357145465301746,0.392995646237324,5730,1
R-HSA-9730414,MITF-M-regulated melanocyte development,3/112,114/11091,0.10826717387040527,0.4357145465301746,0.392995646237324,51176/2766/1029,3
R-HSA-187037,Signaling by NTRK1 (TRKA),3/112,115/11091,0.11039105582154271,0.4357145465301746,0.392995646237324,7425/429/6014,3
R-HSA-1839130,Signaling by activated point mutants of FGFR3,1/112,12/11091,0.11472423550336952,0.4357145465301746,0.392995646237324,2246,1
R-HSA-190873,Gap junction degradation,1/112,12/11091,0.11472423550336952,0.4357145465301746,0.392995646237324,2697,1
R-HSA-2029481,FCGR activation,1/112,12/11091,0.11472423550336952,0.4357145465301746,0.392995646237324,6850,1
R-HSA-2033514,FGFR3 mutant receptor activation,1/112,12/11091,0.11472423550336952,0.4357145465301746,0.392995646237324,2246,1
R-HSA-4641265,Repression of WNT target genes,1/112,12/11091,0.11472423550336952,0.4357145465301746,0.392995646237324,51176,1
R-HSA-6803211,TP53 Regulates Transcription of Death Receptors and Ligands,1/112,12/11091,0.11472423550336952,0.4357145465301746,0.392995646237324,3486,1
R-HSA-73621,Pyrimidine catabolism,1/112,12/11091,0.11472423550336952,0.4357145465301746,0.392995646237324,84618,1
R-HSA-9020558,Interleukin-2 signaling,1/112,12/11091,0.11472423550336952,0.4357145465301746,0.392995646237324,6850,1
R-HSA-9827857,Specification of primordial germ cells,1/112,12/11091,0.11472423550336952,0.4357145465301746,0.392995646237324,7852,1
R-HSA-9831926,Nephron development,1/112,12/11091,0.11472423550336952,0.4357145465301746,0.392995646237324,5455,1
R-HSA-1236394,Signaling by ERBB4,2/112,58/11091,0.11615901139875923,0.4357145465301746,0.392995646237324,348/6387,2
R-HSA-373760,L1CAM interactions,3/112,119/11091,0.11904575283891151,0.4357145465301746,0.392995646237324,7277/1741/2596,3
R-HSA-2142753,Arachidonic acid metabolism,2/112,59/11091,0.11947529168282929,0.4357145465301746,0.392995646237324,5730/8644,2
R-HSA-3000171,Non-integrin membrane-ECM interactions,2/112,59/11091,0.11947529168282929,0.4357145465301746,0.392995646237324,1756/3914,2
R-HSA-380108,Chemokine receptors bind chemokines,2/112,59/11091,0.11947529168282929,0.4357145465301746,0.392995646237324,6387/7852,2
R-HSA-190239,FGFR3 ligand binding and activation,1/112,13/11091,0.12367367910149407,0.4357145465301746,0.392995646237324,2246,1
R-HSA-190372,FGFR3c ligand binding and activation,1/112,13/11091,0.12367367910149407,0.4357145465301746,0.392995646237324,2246,1
R-HSA-190375,FGFR2c ligand binding and activation,1/112,13/11091,0.12367367910149407,0.4357145465301746,0.392995646237324,2246,1
R-HSA-209543,p75NTR recruits signalling complexes,1/112,13/11091,0.12367367910149407,0.4357145465301746,0.392995646237324,4804,1
R-HSA-209560,NF-kB is activated and signals survival,1/112,13/11091,0.12367367910149407,0.4357145465301746,0.392995646237324,4804,1
R-HSA-2168880,Scavenging of heme from plasma,1/112,13/11091,0.12367367910149407,0.4357145465301746,0.392995646237324,8542,1
R-HSA-5654227,Phospholipase C-mediated cascade; FGFR3,1/112,13/11091,0.12367367910149407,0.4357145465301746,0.392995646237324,2246,1
R-HSA-74217,Purine salvage,1/112,13/11091,0.12367367910149407,0.4357145465301746,0.392995646237324,2766,1
R-HSA-75205,Dissolution of Fibrin Clot,1/112,13/11091,0.12367367910149407,0.4357145465301746,0.392995646237324,5054,1
R-HSA-9768759,Regulation of NPAS4 gene expression,1/112,13/11091,0.12367367910149407,0.4357145465301746,0.392995646237324,30818,1
R-HSA-198725,Nuclear Events (kinase and transcription factor activation),2/112,61/11091,0.12617767159894125,0.4357145465301746,0.392995646237324,7425/429,2
R-HSA-2022090,Assembly of collagen fibrils and other multimeric structures,2/112,61/11091,0.12617767159894125,0.4357145465301746,0.392995646237324,1293/3914,2
R-HSA-2559580,Oxidative Stress Induced Senescence,3/112,124/11091,0.13020649586334274,0.4357145465301746,0.392995646237324,4217/23043/1029,3
R-HSA-9006936,Signaling by TGFB family members,3/112,124/11091,0.13020649586334274,0.4357145465301746,0.392995646237324,5054/64388/25937,3
R-HSA-162594,Early Phase of HIV Life Cycle,1/112,14/11091,0.1325334505350233,0.4357145465301746,0.392995646237324,7852,1
R-HSA-166786,Creation of C4 and C2 activators,1/112,14/11091,0.1325334505350233,0.4357145465301746,0.392995646237324,716,1
R-HSA-190322,FGFR4 ligand binding and activation,1/112,14/11091,0.1325334505350233,0.4357145465301746,0.392995646237324,2246,1
R-HSA-190373,FGFR1c ligand binding and activation,1/112,14/11091,0.1325334505350233,0.4357145465301746,0.392995646237324,2246,1
R-HSA-5682910,LGI-ADAM interactions,1/112,14/11091,0.1325334505350233,0.4357145465301746,0.392995646237324,9211,1
R-HSA-8983432,Interleukin-15 signaling,1/112,14/11091,0.1325334505350233,0.4357145465301746,0.392995646237324,3600,1
R-HSA-9796292,Formation of axial mesoderm,1/112,14/11091,0.1325334505350233,0.4357145465301746,0.392995646237324,51176,1
R-HSA-1442490,Collagen degradation,2/112,64/11091,0.13639395842705554,0.44422583416855493,0.4006724589863914,4327/1293,2
R-HSA-9614085,FOXO-mediated transcription,2/112,65/11091,0.1398397164371165,0.44422583416855493,0.4006724589863914,84676/2308,2
R-HSA-2022857,Keratan sulfate degradation,1/112,15/11091,0.14130444029218447,0.44422583416855493,0.4006724589863914,4060,1
R-HSA-2214320,Anchoring fibril formation,1/112,15/11091,0.14130444029218447,0.44422583416855493,0.4006724589863914,3914,1
R-HSA-5654228,Phospholipase C-mediated cascade; FGFR4,1/112,15/11091,0.14130444029218447,0.44422583416855493,0.4006724589863914,2246,1
R-HSA-975577,N-Glycan antennae elongation,1/112,15/11091,0.14130444029218447,0.44422583416855493,0.4006724589863914,9331,1
R-HSA-9823730,Formation of definitive endoderm,1/112,15/11091,0.14130444029218447,0.44422583416855493,0.4006724589863914,7852,1
R-HSA-193639,p75NTR signals via NF-kB,1/112,16/11091,0.14998753009782462,0.4517588481389568,0.4074669112648118,4804,1
R-HSA-205043,NRIF signals cell death from the nucleus,1/112,16/11091,0.14998753009782462,0.4517588481389568,0.4074669112648118,4804,1
R-HSA-2730905,Role of LAT2/NTAL/LAB on calcium mobilization,1/112,16/11091,0.14998753009782462,0.4517588481389568,0.4074669112648118,6850,1
R-HSA-418457,cGMP effects,1/112,16/11091,0.14998753009782462,0.4517588481389568,0.4074669112648118,5136,1
R-HSA-5654219,Phospholipase C-mediated cascade: FGFR1,1/112,16/11091,0.14998753009782462,0.4517588481389568,0.4074669112648118,2246,1
R-HSA-8866427,VLDLR internalisation and degradation,1/112,16/11091,0.14998753009782462,0.4517588481389568,0.4074669112648118,7436,1
R-HSA-9614657,FOXO-mediated transcription of cell death genes,1/112,16/11091,0.14998753009782462,0.4517588481389568,0.4074669112648118,2308,1
R-HSA-166520,Signaling by NTRKs,3/112,134/11091,0.1535684283697402,0.4597911873213055,0.41471173325412297,7425/429/6014,3
R-HSA-2033519,Activated point mutants of FGFR2,1/112,17/11091,0.15858359299886715,0.46108408831462533,0.4158778739428764,2246,1
R-HSA-9617828,FOXO-mediated transcription of cell cycle genes,1/112,17/11091,0.15858359299886715,0.46108408831462533,0.4158778739428764,2308,1
R-HSA-9659787,Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects,1/112,17/11091,0.15858359299886715,0.46108408831462533,0.4158778739428764,1028,1
R-HSA-9661069,"Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)",1/112,17/11091,0.15858359299886715,0.46108408831462533,0.4158778739428764,1028,1
R-HSA-9754189,Germ layer formation at gastrulation,1/112,17/11091,0.15858359299886715,0.46108408831462533,0.4158778739428764,51176,1
R-HSA-181430,Norepinephrine Neurotransmitter Release Cycle,1/112,18/11091,0.1670934934489421,0.46435374146308217,0.4188269594445713,4128,1
R-HSA-190242,FGFR1 ligand binding and activation,1/112,18/11091,0.1670934934489421,0.46435374146308217,0.4188269594445713,2246,1
R-HSA-209776,Metabolism of amine-derived hormones,1/112,18/11091,0.1670934934489421,0.46435374146308217,0.4188269594445713,1735,1
R-HSA-5654221,Phospholipase C-mediated cascade; FGFR2,1/112,18/11091,0.1670934934489421,0.46435374146308217,0.4188269594445713,2246,1
R-HSA-5654704,SHC-mediated cascade:FGFR3,1/112,18/11091,0.1670934934489421,0.46435374146308217,0.4188269594445713,2246,1
R-HSA-5654710,PI-3K cascade:FGFR3,1/112,18/11091,0.1670934934489421,0.46435374146308217,0.4188269594445713,2246,1
R-HSA-5676594,TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway,1/112,18/11091,0.1670934934489421,0.46435374146308217,0.4188269594445713,4050,1
R-HSA-74259,Purine catabolism,1/112,18/11091,0.1670934934489421,0.46435374146308217,0.4188269594445713,84618,1
R-HSA-71387,Metabolism of carbohydrates,5/112,290/11091,0.16959945144366892,0.46466104188567126,0.41910413111378947,4060/8534/166012/9331/51363,5
R-HSA-174824,"Plasma lipoprotein assembly, remodeling, and clearance",2/112,75/11091,0.17522285978219765,0.46466104188567126,0.41910413111378947,348/7436,2
R-HSA-3000480,Scavenging by Class A Receptors,1/112,19/11091,0.17551808739220187,0.46466104188567126,0.41910413111378947,348,1
R-HSA-416700,Other semaphorin interactions,1/112,19/11091,0.17551808739220187,0.46466104188567126,0.41910413111378947,5788,1
R-HSA-422085,"Synthesis, secretion, and deacylation of Ghrelin",1/112,19/11091,0.17551808739220187,0.46466104188567126,0.41910413111378947,43,1
R-HSA-8851708,Signaling by FGFR2 IIIa TM,1/112,19/11091,0.17551808739220187,0.46466104188567126,0.41910413111378947,2246,1
R-HSA-888590,"GABA synthesis, release, reuptake and degradation",1/112,19/11091,0.17551808739220187,0.46466104188567126,0.41910413111378947,2571,1
R-HSA-8963898,Plasma lipoprotein assembly,1/112,19/11091,0.17551808739220187,0.46466104188567126,0.41910413111378947,348,1
R-HSA-9840309,Glycosphingolipid biosynthesis,1/112,19/11091,0.17551808739220187,0.46466104188567126,0.41910413111378947,9331,1
R-HSA-9006931,Signaling by Nuclear Receptors,5/112,298/11091,0.18312183034409585,0.46707417091011405,0.4212806689594206,348/8644/6387/8204/1382,5
R-HSA-111471,Apoptotic factor-mediated response,1/112,20/11091,0.1838582223463272,0.46707417091011405,0.4212806689594206,1029,1
R-HSA-190241,FGFR2 ligand binding and activation,1/112,20/11091,0.1838582223463272,0.46707417091011405,0.4212806689594206,2246,1
R-HSA-2028269,Signaling by Hippo,1/112,20/11091,0.1838582223463272,0.46707417091011405,0.4212806689594206,25937,1
R-HSA-3232118,SUMOylation of transcription factors,1/112,20/11091,0.1838582223463272,0.46707417091011405,0.4212806689594206,1029,1
R-HSA-5654706,FRS-mediated FGFR3 signaling,1/112,20/11091,0.1838582223463272,0.46707417091011405,0.4212806689594206,2246,1
R-HSA-5654719,SHC-mediated cascade:FGFR4,1/112,20/11091,0.1838582223463272,0.46707417091011405,0.4212806689594206,2246,1
R-HSA-5654720,PI-3K cascade:FGFR4,1/112,20/11091,0.1838582223463272,0.46707417091011405,0.4212806689594206,2246,1
R-HSA-210745,Regulation of gene expression in beta cells,1/112,21/11091,0.19211473748472552,0.48076474106874095,0.43362897018023927,2308,1
R-HSA-5654688,SHC-mediated cascade:FGFR1,1/112,21/11091,0.19211473748472552,0.48076474106874095,0.43362897018023927,2246,1
R-HSA-5654689,PI-3K cascade:FGFR1,1/112,21/11091,0.19211473748472552,0.48076474106874095,0.43362897018023927,2246,1
R-HSA-140875,Common Pathway of Fibrin Clot Formation,1/112,22/11091,0.20028846371794262,0.48203395813457006,0.434773748992361,57126,1
R-HSA-202427,Phosphorylation of CD3 and TCR zeta chains,1/112,22/11091,0.20028846371794262,0.48203395813457006,0.434773748992361,5788,1
R-HSA-389977,Post-chaperonin tubulin folding pathway,1/112,22/11091,0.20028846371794262,0.48203395813457006,0.434773748992361,7277,1
R-HSA-392154,Nitric oxide stimulates guanylate cyclase,1/112,22/11091,0.20028846371794262,0.48203395813457006,0.434773748992361,5136,1
R-HSA-5365859,RA biosynthesis pathway,1/112,22/11091,0.20028846371794262,0.48203395813457006,0.434773748992361,8644,1
R-HSA-5654712,FRS-mediated FGFR4 signaling,1/112,22/11091,0.20028846371794262,0.48203395813457006,0.434773748992361,2246,1
R-HSA-5655332,Signaling by FGFR3 in disease,1/112,22/11091,0.20028846371794262,0.48203395813457006,0.434773748992361,2246,1
R-HSA-912631,Regulation of signaling by CBL,1/112,22/11091,0.20028846371794262,0.48203395813457006,0.434773748992361,6850,1
R-HSA-73887,Death Receptor Signaling,3/112,154/11091,0.20371168653217384,0.4875128025974995,0.4397154293596783,4804/7124/84894,3
R-HSA-381340,Transcriptional regulation of white adipocyte differentiation,2/112,84/11091,0.2081377414179305,0.4875128025974995,0.4397154293596783,7124/1052,2
R-HSA-5654693,FRS-mediated FGFR1 signaling,1/112,23/11091,0.20838022377427912,0.4875128025974995,0.4397154293596783,2246,1
R-HSA-5654695,PI-3K cascade:FGFR2,1/112,23/11091,0.20838022377427912,0.4875128025974995,0.4397154293596783,2246,1
R-HSA-5654699,SHC-mediated cascade:FGFR2,1/112,23/11091,0.20838022377427912,0.4875128025974995,0.4397154293596783,2246,1
R-HSA-8956321,Nucleotide salvage,1/112,23/11091,0.20838022377427912,0.4875128025974995,0.4397154293596783,2766,1
R-HSA-418555,G alpha (s) signalling events,3/112,158/11091,0.21417410528612543,0.49706392601673355,0.4483301289383952,7434/7432/5136,3
R-HSA-8940973,RUNX2 regulates osteoblast differentiation,1/112,24/11091,0.21639083227963563,0.49706392601673355,0.4483301289383952,25937,1
R-HSA-2980736,Peptide hormone metabolism,2/112,88/11091,0.22297609674015484,0.49706392601673355,0.4483301289383952,43/5126,2
R-HSA-2029485,Role of phospholipids in phagocytosis,1/112,25/11091,0.22432109583657756,0.49706392601673355,0.4483301289383952,6850,1
R-HSA-264876,Insulin processing,1/112,25/11091,0.22432109583657756,0.49706392601673355,0.4483301289383952,5126,1
R-HSA-389960,Formation of tubulin folding intermediates by CCT/TriC,1/112,25/11091,0.22432109583657756,0.49706392601673355,0.4483301289383952,7277,1
R-HSA-5357786,TNFR1-induced proapoptotic signaling,1/112,25/11091,0.22432109583657756,0.49706392601673355,0.4483301289383952,7124,1
R-HSA-5654700,FRS-mediated FGFR2 signaling,1/112,25/11091,0.22432109583657756,0.49706392601673355,0.4483301289383952,2246,1
R-HSA-5654708,Downstream signaling of activated FGFR3,1/112,25/11091,0.22432109583657756,0.49706392601673355,0.4483301289383952,2246,1
R-HSA-5674400,Constitutive Signaling by AKT1 E17K in Cancer,1/112,25/11091,0.22432109583657756,0.49706392601673355,0.4483301289383952,2308,1
R-HSA-9705462,Inactivation of CSF3 (G-CSF) signaling,1/112,25/11091,0.22432109583657756,0.49706392601673355,0.4483301289383952,6850,1
R-HSA-9734009,Defective Intrinsic Pathway for Apoptosis,1/112,25/11091,0.22432109583657756,0.49706392601673355,0.4483301289383952,1029,1
R-HSA-1474290,Collagen formation,2/112,90/11091,0.2304280898428422,0.5055516103490503,0.45598565252786577,1293/3914,2
R-HSA-9660826,Purinergic signaling in leishmaniasis infection,1/112,26/11091,0.23217181310264534,0.5055516103490503,0.45598565252786577,718,1
R-HSA-9664424,Cell recruitment (pro-inflammatory response),1/112,26/11091,0.23217181310264534,0.5055516103490503,0.45598565252786577,718,1
R-HSA-975576,N-glycan antennae elongation in the medial/trans-Golgi,1/112,26/11091,0.23217181310264534,0.5055516103490503,0.45598565252786577,9331,1
R-HSA-354192,Integrin signaling,1/112,27/11091,0.23994377486789664,0.5179902092641717,0.46720472992122636,6850,1
R-HSA-5654716,Downstream signaling of activated FGFR4,1/112,27/11091,0.23994377486789664,0.5179902092641717,0.46720472992122636,2246,1
R-HSA-170834,Signaling by TGF-beta Receptor Complex,2/112,94/11091,0.24537876748931658,0.5274594873808813,0.47574560858252557,5054/25937,2
R-HSA-389957,Prefoldin mediated transfer of substrate  to CCT/TriC,1/112,28/11091,0.24763776413170668,0.5278042176196969,0.4760565403245565,7277,1
R-HSA-5621480,Dectin-2 family,1/112,28/11091,0.24763776413170668,0.5278042176196969,0.4760565403245565,6850,1
R-HSA-373080,Class B/2 (Secretin family receptors),2/112,95/11091,0.24912354355419258,0.5287305586825269,0.47689205983502997,7434/7432,2
R-HSA-5654732,Negative regulation of FGFR3 signaling,1/112,29/11091,0.25525455617882276,0.5306144503802215,0.47859124853798357,2246,1
R-HSA-5669034,TNFs bind their physiological receptors,1/112,29/11091,0.25525455617882276,0.5306144503802215,0.47859124853798357,7293,1
R-HSA-9619483,Activation of AMPK downstream of NMDARs,1/112,29/11091,0.25525455617882276,0.5306144503802215,0.47859124853798357,7277,1
R-HSA-193704,p75 NTR receptor-mediated signalling,2/112,97/11091,0.256618612316708,0.5306144503802215,0.47859124853798357,4804/84894,2
R-HSA-201556,Signaling by ALK,1/112,30/11091,0.26279491865468374,0.5306144503802215,0.47859124853798357,4613,1
R-HSA-2173795,Downregulation of SMAD2/3:SMAD4 transcriptional activity,1/112,30/11091,0.26279491865468374,0.5306144503802215,0.47859124853798357,25937,1
R-HSA-2424491,DAP12 signaling,1/112,30/11091,0.26279491865468374,0.5306144503802215,0.47859124853798357,6850,1
R-HSA-5654696,Downstream signaling of activated FGFR2,1/112,30/11091,0.26279491865468374,0.5306144503802215,0.47859124853798357,2246,1
R-HSA-8874081,MET activates PTK2 signaling,1/112,30/11091,0.26279491865468374,0.5306144503802215,0.47859124853798357,3914,1
R-HSA-9674555,Signaling by CSF3 (G-CSF),1/112,30/11091,0.26279491865468374,0.5306144503802215,0.47859124853798357,6850,1
R-HSA-15869,Metabolism of nucleotides,2/112,99/11091,0.2641182917635971,0.5306144503802215,0.47859124853798357,84618/2766,2
R-HSA-1839124,FGFR1 mutant receptor activation,1/112,31/11091,0.27025961164000845,0.5306144503802215,0.47859124853798357,2246,1
R-HSA-201451,Signaling by BMP,1/112,31/11091,0.27025961164000845,0.5306144503802215,0.47859124853798357,64388,1
R-HSA-2122948,Activated NOTCH1 Transmits Signal to the Nucleus,1/112,31/11091,0.27025961164000845,0.5306144503802215,0.47859124853798357,8788,1
R-HSA-5654687,Downstream signaling of activated FGFR1,1/112,31/11091,0.27025961164000845,0.5306144503802215,0.47859124853798357,2246,1
R-HSA-5654733,Negative regulation of FGFR4 signaling,1/112,31/11091,0.27025961164000845,0.5306144503802215,0.47859124853798357,2246,1
R-HSA-917977,Transferrin endocytosis and recycling,1/112,31/11091,0.27025961164000845,0.5306144503802215,0.47859124853798357,7018,1
R-HSA-9668328,Sealing of the nuclear envelope (NE) by ESCRT-III,1/112,31/11091,0.27025961164000845,0.5306144503802215,0.47859124853798357,7277,1
R-HSA-5607764,CLEC7A (Dectin-1) signaling,2/112,101/11091,0.2716193993572593,0.5306144503802215,0.47859124853798357,6850/84433,2
R-HSA-2871796,FCERI mediated MAPK activation,1/112,32/11091,0.2776493877246663,0.5306144503802215,0.47859124853798357,6850,1
R-HSA-389958,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,1/112,32/11091,0.2776493877246663,0.5306144503802215,0.47859124853798357,7277,1
R-HSA-5626467,RHO GTPases activate IQGAPs,1/112,32/11091,0.2776493877246663,0.5306144503802215,0.47859124853798357,7277,1
R-HSA-8941326,RUNX2 regulates bone development,1/112,32/11091,0.2776493877246663,0.5306144503802215,0.47859124853798357,25937,1
R-HSA-983695,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,1/112,32/11091,0.2776493877246663,0.5306144503802215,0.47859124853798357,6850,1
R-HSA-2219528,PI3K/AKT Signaling in Cancer,2/112,104/11091,0.2828670805311675,0.5306144503802215,0.47859124853798357,2308/2246,2
R-HSA-1839126,FGFR2 mutant receptor activation,1/112,33/11091,0.28496499208083226,0.5306144503802215,0.47859124853798357,2246,1
R-HSA-2559585,Oncogene Induced Senescence,1/112,33/11091,0.28496499208083226,0.5306144503802215,0.47859124853798357,1029,1
R-HSA-2871809,FCERI mediated Ca+2 mobilization,1/112,33/11091,0.28496499208083226,0.5306144503802215,0.47859124853798357,6850,1
R-HSA-5357956,TNFR1-induced NF-kappa-B signaling pathway,1/112,33/11091,0.28496499208083226,0.5306144503802215,0.47859124853798357,7124,1
R-HSA-5654726,Negative regulation of FGFR1 signaling,1/112,33/11091,0.28496499208083226,0.5306144503802215,0.47859124853798357,2246,1
R-HSA-5694530,Cargo concentration in the ER,1/112,33/11091,0.28496499208083226,0.5306144503802215,0.47859124853798357,149111,1
R-HSA-948021,Transport to the Golgi and subsequent modification,3/112,185/11091,0.2871831750451,0.5306144503802215,0.47859124853798357,7277/149111/9331,3
R-HSA-211945,Phase I - Functionalization of compounds,2/112,106/11091,0.29035863855200983,0.5306144503802215,0.47859124853798357,4128/4129,2
R-HSA-6811558,"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",2/112,106/11091,0.29035863855200983,0.5306144503802215,0.47859124853798357,90865/2246,2
R-HSA-8856825,Cargo recognition for clathrin-mediated endocytosis,2/112,106/11091,0.29035863855200983,0.5306144503802215,0.47859124853798357,6572/7018,2
R-HSA-187687,Signalling to ERKs,1/112,34/11091,0.2922071625354301,0.5306144503802215,0.47859124853798357,6014,1
R-HSA-5579029,Metabolic disorders of biological oxidation enzymes,1/112,34/11091,0.2922071625354301,0.5306144503802215,0.47859124853798357,4128,1
R-HSA-5654727,Negative regulation of FGFR2 signaling,1/112,34/11091,0.2922071625354301,0.5306144503802215,0.47859124853798357,2246,1
R-HSA-8963899,Plasma lipoprotein remodeling,1/112,34/11091,0.2922071625354301,0.5306144503802215,0.47859124853798357,348,1
R-HSA-9634815,Transcriptional Regulation by NPAS4,1/112,34/11091,0.2922071625354301,0.5306144503802215,0.47859124853798357,30818,1
R-HSA-114604,GPVI-mediated activation cascade,1/112,35/11091,0.2993766296418817,0.5390086738665387,0.4861624744929961,6850,1
R-HSA-9687139,Aberrant regulation of mitotic cell cycle due to RB1 defects,1/112,35/11091,0.2993766296418817,0.5390086738665387,0.4861624744929961,1028,1
R-HSA-2672351,Stimuli-sensing channels,2/112,109/11091,0.3015787187065013,0.5390086738665387,0.4861624744929961,8989/80036,2
R-HSA-9843745,Adipogenesis,2/112,109/11091,0.3015787187065013,0.5390086738665387,0.4861624744929961,7124/1052,2
R-HSA-977225,Amyloid fiber formation,2/112,110/11091,0.3053128238025652,0.5390086738665387,0.4861624744929961,348/54959,2
R-HSA-390522,Striated Muscle Contraction,1/112,36/11091,0.3064741167511532,0.5390086738665387,0.4861624744929961,1756,1
R-HSA-6804757,Regulation of TP53 Degradation,1/112,36/11091,0.3064741167511532,0.5390086738665387,0.4861624744929961,1029,1
R-HSA-8956319,Nucleotide catabolism,1/112,36/11091,0.3064741167511532,0.5390086738665387,0.4861624744929961,84618,1
R-HSA-9824585,Regulation of MITF-M-dependent genes involved in pigmentation,1/112,36/11091,0.3064741167511532,0.5390086738665387,0.4861624744929961,51176,1
R-HSA-983705,Signaling by the B Cell Receptor (BCR),2/112,112/11091,0.3127702528358929,0.5400365447305073,0.4870895694859238,6850/84433,2
R-HSA-111933,Calmodulin induced events,1/112,37/11091,0.3135003400821236,0.5400365447305073,0.4870895694859238,5136,1
R-HSA-111997,CaM pathway,1/112,37/11091,0.3135003400821236,0.5400365447305073,0.4870895694859238,5136,1
R-HSA-6806003,Regulation of TP53 Expression and Degradation,1/112,37/11091,0.3135003400821236,0.5400365447305073,0.4870895694859238,1029,1
R-HSA-9029569,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,1/112,37/11091,0.3135003400821236,0.5400365447305073,0.4870895694859238,348,1
R-HSA-9675126,Diseases of mitotic cell cycle,1/112,37/11091,0.3135003400821236,0.5400365447305073,0.4870895694859238,1028,1
R-HSA-2559583,Cellular Senescence,3/112,195/11091,0.31482682043294563,0.5404706166476848,0.48748108355164205,4217/23043/1029,3
R-HSA-199418,Negative regulation of the PI3K/AKT network,2/112,113/11091,0.31649296684449446,0.5414828650434719,0.48839408775502,90865/2246,2
R-HSA-5655302,Signaling by FGFR1 in disease,1/112,38/11091,0.3204560087912607,0.5427251596700475,0.48951458369318923,2246,1
R-HSA-8864260,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,1/112,38/11091,0.3204560087912607,0.5427251596700475,0.48951458369318923,348,1
R-HSA-9607240,FLT3 Signaling,1/112,38/11091,0.3204560087912607,0.5427251596700475,0.48951458369318923,6850,1
R-HSA-196854,Metabolism of vitamins and cofactors,3/112,198/11091,0.32314069214314795,0.5452084039600728,0.4917543624710502,348/8644/1645,3
R-HSA-111996,Ca-dependent events,1/112,39/11091,0.3273418250416341,0.5452084039600728,0.4917543624710502,5136,1
R-HSA-140877,Formation of Fibrin Clot (Clotting Cascade),1/112,39/11091,0.3273418250416341,0.5452084039600728,0.4917543624710502,57126,1
R-HSA-76009,Platelet Aggregation (Plug Formation),1/112,39/11091,0.3273418250416341,0.5452084039600728,0.4917543624710502,6850,1
R-HSA-9856649,Transcriptional and post-translational regulation of MITF-M expression and activity,1/112,39/11091,0.3273418250416341,0.5452084039600728,0.4917543624710502,51176,1
R-HSA-375276,Peptide ligand-binding receptors,3/112,201/11091,0.33145695584618995,0.5474974511004551,0.4938189838323661,718/6387/7852,3
R-HSA-5654741,Signaling by FGFR3,1/112,40/11091,0.3341584840712519,0.5474974511004551,0.4938189838323661,2246,1
R-HSA-9664323,FCGR3A-mediated IL10 synthesis,1/112,40/11091,0.3341584840712519,0.5474974511004551,0.4938189838323661,6850,1
R-HSA-9725554,Differentiation of keratinocytes in interfollicular epidermis in mammalian skin,1/112,40/11091,0.3341584840712519,0.5474974511004551,0.4938189838323661,11005,1
R-HSA-9734767,Developmental Cell Lineages,1/112,40/11091,0.3341584840712519,0.5474974511004551,0.4938189838323661,11005,1
R-HSA-186712,Regulation of beta-cell development,1/112,41/11091,0.34090667426073906,0.5513699586918063,0.49731181792648005,2308,1
R-HSA-3560782,Diseases associated with glycosaminoglycan metabolism,1/112,41/11091,0.34090667426073906,0.5513699586918063,0.49731181792648005,4060,1
R-HSA-5654743,Signaling by FGFR4,1/112,41/11091,0.34090667426073906,0.5513699586918063,0.49731181792648005,2246,1
R-HSA-8875878,MET promotes cell motility,1/112,41/11091,0.34090667426073906,0.5513699586918063,0.49731181792648005,3914,1
R-HSA-202403,TCR signaling,2/112,120/11091,0.34241310760620347,0.5515340688699695,0.49745983819808903,5788/84433,2
R-HSA-3769402,Deactivation of the beta-catenin transactivating complex,1/112,42/11091,0.34758707720035853,0.5515340688699695,0.49745983819808903,51176,1
R-HSA-3928662,EPHB-mediated forward signaling,1/112,42/11091,0.34758707720035853,0.5515340688699695,0.49745983819808903,2902,1
R-HSA-419037,NCAM1 interactions,1/112,42/11091,0.34758707720035853,0.5515340688699695,0.49745983819808903,1293,1
R-HSA-8955332,Carboxyterminal post-translational modifications of tubulin,1/112,42/11091,0.34758707720035853,0.5515340688699695,0.49745983819808903,7277,1
R-HSA-9035034,RHOF GTPase cycle,1/112,42/11091,0.34758707720035853,0.5515340688699695,0.49745983819808903,10409,1
R-HSA-1489509,DAG and IP3 signaling,1/112,43/11091,0.3542003677563871,0.5567587030670709,0.5021722319177724,5136,1
R-HSA-5655253,Signaling by FGFR2 in disease,1/112,43/11091,0.3542003677563871,0.5567587030670709,0.5021722319177724,2246,1
R-HSA-9646399,Aggrephagy,1/112,43/11091,0.3542003677563871,0.5567587030670709,0.5021722319177724,7277,1
R-HSA-9758941,Gastrulation,2/112,125/11091,0.3607442464062165,0.560048915774174,0.5051398612507462,51176/7852,2
R-HSA-109704,PI3K Cascade,1/112,44/11091,0.36074721413684374,0.560048915774174,0.5051398612507462,2246,1
R-HSA-5633008,TP53 Regulates Transcription of Cell Death Genes,1/112,44/11091,0.36074721413684374,0.560048915774174,0.5051398612507462,3486,1
R-HSA-8948216,Collagen chain trimerization,1/112,44/11091,0.36074721413684374,0.560048915774174,0.5051398612507462,1293,1
R-HSA-2172127,DAP12 interactions,1/112,45/11091,0.36722827795658386,0.5666129564790235,0.5110603416186233,6850,1
R-HSA-3899300,SUMOylation of transcription cofactors,1/112,45/11091,0.36722827795658386,0.5666129564790235,0.5110603416186233,8204,1
R-HSA-9830369,Kidney development,1/112,46/11091,0.37364421430176453,0.574749357167546,0.5183990225786593,5455,1
R-HSA-1483206,Glycerophospholipid biosynthesis,2/112,129/11091,0.37527606158058113,0.5754995700458302,0.5190756820963751,43/1103,2
R-HSA-437239,Recycling pathway of L1,1/112,47/11091,0.37999567179367966,0.5782752863212729,0.521579257935479,7277,1
R-HSA-6783783,Interleukin-10 signaling,1/112,47/11091,0.37999567179367966,0.5782752863212729,0.521579257935479,7124,1
R-HSA-376176,Signaling by ROBO receptors,3/112,219/11091,0.3811961174786953,0.5782752863212729,0.521579257935479,9423/6387/7852,3
R-HSA-9006925,Intracellular signaling by second messengers,4/112,310/11091,0.3824891614221171,0.5782752863212729,0.521579257935479,2308/90865/5136/2246,4
R-HSA-112399,IRS-mediated signalling,1/112,48/11091,0.38628329265198347,0.5782752863212729,0.521579257935479,2246,1
R-HSA-512988,"Interleukin-3, Interleukin-5 and GM-CSF signaling",1/112,48/11091,0.38628329265198347,0.5782752863212729,0.521579257935479,6850,1
R-HSA-5357905,Regulation of TNFR1 signaling,1/112,48/11091,0.38628329265198347,0.5782752863212729,0.521579257935479,7124,1
R-HSA-9707616,Heme signaling,1/112,48/11091,0.38628329265198347,0.5782752863212729,0.521579257935479,8204,1
R-HSA-2454202,Fc epsilon receptor (FCERI) signaling,2/112,134/11091,0.39325205786771744,0.5869607866690263,0.5294132030016748,6850/84433,2
R-HSA-418594,G alpha (i) signalling events,4/112,318/11091,0.40086615924122426,0.5965552606459639,0.5380670029055361,718/6387/7852/5136,4
R-HSA-112043,PLC beta mediated events,1/112,51/11091,0.40476946290767735,0.5988207054192992,0.5401103359542072,5136,1
R-HSA-6811436,COPI-independent Golgi-to-ER retrograde traffic,1/112,51/11091,0.40476946290767735,0.5988207054192992,0.5401103359542072,7277,1
R-HSA-5654736,Signaling by FGFR1,1/112,52/11091,0.41080803357383144,0.6059719674124259,0.5465604644862521,2246,1
R-HSA-5683057,MAPK family signaling cascades,4/112,325/11091,0.41687555578042335,0.6131239899343653,0.5530112789823406,2902/2308/1741/2246,4
R-HSA-74751,Insulin receptor signalling cascade,1/112,54/11091,0.42270362184029553,0.6176693620827961,0.5571110077590983,2246,1
R-HSA-5621481,C-type lectin receptors (CLRs),2/112,143/11091,0.42501010197282085,0.6176693620827961,0.5571110077590983,6850/84433,2
R-HSA-109606,Intrinsic Pathway for Apoptosis,1/112,55/11091,0.4285618436717611,0.6176693620827961,0.5571110077590983,1029,1
R-HSA-3371497,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,1/112,55/11091,0.4285618436717611,0.6176693620827961,0.5571110077590983,7277,1
R-HSA-8941858,Regulation of RUNX3 expression and activity,1/112,55/11091,0.4285618436717611,0.6176693620827961,0.5571110077590983,1029,1
R-HSA-9013409,RHOJ GTPase cycle,1/112,55/11091,0.4285618436717611,0.6176693620827961,0.5571110077590983,2697,1
R-HSA-9824272,Somitogenesis,1/112,55/11091,0.4285618436717611,0.6176693620827961,0.5571110077590983,51176,1
R-HSA-112040,G-protein mediated events,1/112,56/11091,0.4343611435547591,0.6237909673099794,0.5626324304919977,5136,1
R-HSA-8856828,Clathrin-mediated endocytosis,2/112,146/11091,0.4354084809843908,0.6237909673099794,0.5626324304919977,6572/7018,2
R-HSA-69541,Stabilization of p53,1/112,57/11091,0.44010210883993073,0.6237909673099794,0.5626324304919977,1029,1
R-HSA-75893,TNF signaling,1/112,57/11091,0.44010210883993073,0.6237909673099794,0.5626324304919977,7124,1
R-HSA-1169410,Antiviral mechanism by IFN-stimulated genes,2/112,149/11091,0.4457066579817047,0.6237909673099794,0.5626324304919977,7277/3434,2
R-HSA-453279,Mitotic G1 phase and G1/S transition,2/112,149/11091,0.4457066579817047,0.6237909673099794,0.5626324304919977,1028/1029,2
R-HSA-9018519,Estrogen-dependent gene expression,2/112,149/11091,0.4457066579817047,0.6237909673099794,0.5626324304919977,6387/8204,2
R-HSA-1660662,Glycosphingolipid metabolism,1/112,58/11091,0.4457853210757404,0.6237909673099794,0.5626324304919977,9331,1
R-HSA-917937,Iron uptake and transport,1/112,58/11091,0.4457853210757404,0.6237909673099794,0.5626324304919977,7018,1
R-HSA-193648,NRAGE signals death through JNK,1/112,59/11091,0.4514113560652734,0.6237909673099794,0.5626324304919977,4804,1
R-HSA-9013406,RHOQ GTPase cycle,1/112,59/11091,0.4514113560652734,0.6237909673099794,0.5626324304919977,2697,1
R-HSA-9664407,Parasite infection,1/112,59/11091,0.4514113560652734,0.6237909673099794,0.5626324304919977,6850,1
R-HSA-9664417,Leishmania phagocytosis,1/112,59/11091,0.4514113560652734,0.6237909673099794,0.5626324304919977,6850,1
R-HSA-9664422,FCGR3A-mediated phagocytosis,1/112,59/11091,0.4514113560652734,0.6237909673099794,0.5626324304919977,6850,1
R-HSA-983189,Kinesins,1/112,59/11091,0.4514113560652734,0.6237909673099794,0.5626324304919977,7277,1
R-HSA-2029482,Regulation of actin dynamics for phagocytic cup formation,1/112,61/11091,0.46249416912787134,0.6358120636439079,0.5734749386429304,6850,1
R-HSA-199977,ER to Golgi Anterograde Transport,2/112,154/11091,0.4626385989933802,0.6358120636439079,0.5734749386429304,7277/149111,2
R-HSA-8957322,Metabolism of steroids,2/112,155/11091,0.46598922289487876,0.637885884833593,0.5753454355200974,8644/1645,2
R-HSA-4086398,Ca2+ pathway,1/112,62/11091,0.4679520705836895,0.637885884833593,0.5753454355200974,51176,1
R-HSA-8986944,Transcriptional Regulation by MECP2,1/112,62/11091,0.4679520705836895,0.637885884833593,0.5753454355200974,2571,1
R-HSA-1226099,Signaling by FGFR in disease,1/112,63/11091,0.47335504166852305,0.6417724688929032,0.5788509659785315,2246,1
R-HSA-375165,NCAM signaling for neurite out-growth,1/112,63/11091,0.47335504166852305,0.6417724688929032,0.5788509659785315,1293,1
R-HSA-913709,O-linked glycosylation of mucins,1/112,64/11091,0.47870363029140317,0.6472793710660639,0.5838179531850446,9331,1
R-HSA-9609646,HCMV Infection,2/112,160/11091,0.48255798370382597,0.6507417313754007,0.5869408521979652,7277/1052,2
R-HSA-373755,Semaphorin interactions,1/112,65/11091,0.48399837894537656,0.6509389962821509,0.5871187765985288,5788,1
R-HSA-69563,p53-Dependent G1 DNA Damage Response,1/112,66/11091,0.4892398247605514,0.6544883825919079,0.5903201692939463,1029,1
R-HSA-69580,p53-Dependent G1/S DNA damage checkpoint,1/112,66/11091,0.4892398247605514,0.6544883825919079,0.5903201692939463,1029,1
R-HSA-1169091,Activation of NF-kappaB in B cells,1/112,67/11091,0.4944284995566348,0.6559999299943613,0.5916835195721873,84433,1
R-HSA-1650814,Collagen biosynthesis and modifying enzymes,1/112,67/11091,0.4944284995566348,0.6559999299943613,0.5916835195721873,1293,1
R-HSA-9658195,Leishmania infection,2/112,164/11091,0.49558642822635646,0.6559999299943613,0.5916835195721873,718/6850,2
R-HSA-9824443,Parasitic Infection Pathways,2/112,164/11091,0.49558642822635646,0.6559999299943613,0.5916835195721873,718/6850,2
R-HSA-204005,COPII-mediated vesicle transport,1/112,68/11091,0.4995649298949564,0.6578040830815787,0.59331078750269,149111,1
R-HSA-69615,G1/S DNA Damage Checkpoints,1/112,68/11091,0.4995649298949564,0.6578040830815787,0.59331078750269,1029,1
R-HSA-9793380,Formation of paraxial mesoderm,1/112,69/11091,0.504649637129989,0.6627644059435626,0.5977847838478089,51176,1
R-HSA-380259,Loss of Nlp from mitotic centrosomes,1/112,70/11091,0.5096831374603684,0.6657556963745214,0.6004827982367242,7277,1
R-HSA-380284,Loss of proteins required for interphase microtubule organization from the centrosome,1/112,70/11091,0.5096831374603684,0.6657556963745214,0.6004827982367242,7277,1
R-HSA-1257604,PIP3 activates AKT signaling,3/112,268/11091,0.5108980095438673,0.6657556963745214,0.6004827982367242,2308/90865/2246,3
R-HSA-500792,GPCR ligand binding,5/112,468/11091,0.5137273673262207,0.6677128314343386,0.6022480492794808,7434/718/6387/7852/7432,5
R-HSA-1445148,Translocation of SLC2A4 (GLUT4) to the plasma membrane,1/112,72/11091,0.5195985567251798,0.6736032835896018,0.6075609819548359,7277,1
R-HSA-1169408,ISG15 antiviral mechanism,1/112,73/11091,0.52448148272997,0.6747165877574806,0.6085651340870024,3434,1
R-HSA-5654738,Signaling by FGFR2,1/112,73/11091,0.52448148272997,0.6747165877574806,0.6085651340870024,2246,1
R-HSA-8854518,AURKA Activation by TPX2,1/112,73/11091,0.52448148272997,0.6747165877574806,0.6085651340870024,7277,1
R-HSA-1980143,Signaling by NOTCH1,1/112,74/11091,0.5293152160694365,0.679197841027874,0.6126070304133382,8788,1
R-HSA-8978868,Fatty acid metabolism,2/112,176/11091,0.5334142837002811,0.6801327207577504,0.6134502514316008,5730/8644,2
R-HSA-2995410,Nuclear Envelope (NE) Reassembly,1/112,75/11091,0.534100247911156,0.6801327207577504,0.6134502514316008,7277,1
R-HSA-9833482,PKR-mediated signaling,1/112,75/11091,0.534100247911156,0.6801327207577504,0.6134502514316008,7277,1
R-HSA-204998,"Cell death signalling via NRAGE, NRIF and NADE",1/112,76/11091,0.5388370645627492,0.6834841305058126,0.6164730778445228,4804,1
R-HSA-5673001,RAF/MAP kinase cascade,3/112,280/11091,0.5405594933653646,0.6834841305058126,0.6164730778445228,2902/1741/2246,3
R-HSA-3108214,SUMOylation of DNA damage response and repair proteins,1/112,77/11091,0.5435261475195329,0.6834841305058126,0.6164730778445228,1029,1
R-HSA-8852276,The role of GTSE1 in G2/M progression after G2 checkpoint,1/112,77/11091,0.5435261475195329,0.6834841305058126,0.6164730778445228,7277,1
R-HSA-909733,Interferon alpha/beta signaling,1/112,77/11091,0.5435261475195329,0.6834841305058126,0.6164730778445228,3434,1
R-HSA-2219530,Constitutive Signaling by Aberrant PI3K in Cancer,1/112,78/11091,0.5481679735117075,0.6876022211381269,0.6201874172031656,2246,1
R-HSA-6806834,Signaling by MET,1/112,79/11091,0.5527630145510873,0.6876064175429257,0.62019120217851,3914,1
R-HSA-9662851,Anti-inflammatory response favouring Leishmania parasite infection,1/112,79/11091,0.5527630145510873,0.6876064175429257,0.62019120217851,6850,1
R-HSA-9664433,Leishmania parasite growth and survival,1/112,79/11091,0.5527630145510873,0.6876064175429257,0.62019120217851,6850,1
R-HSA-3108232,SUMO E3 ligases SUMOylate target proteins,2/112,183/11091,0.554581456255888,0.6876064175429257,0.62019120217851,8204/1029,2
R-HSA-5684996,MAPK1/MAPK3 signaling,3/112,286/11091,0.5550063728080077,0.6876064175429257,0.62019120217851,2902/1741/2246,3
R-HSA-9663891,Selective autophagy,1/112,81/11091,0.5618146065039875,0.6913467363264796,0.623564807694282,7277,1
R-HSA-983712,Ion channel transport,2/112,186/11091,0.5634459231260678,0.6913467363264796,0.623564807694282,8989/80036,2
R-HSA-2871837,FCERI mediated NF-kB activation,1/112,82/11091,0.5662720782634385,0.6913467363264796,0.623564807694282,84433,1
R-HSA-380270,Recruitment of mitotic centrosome proteins and complexes,1/112,82/11091,0.5662720782634385,0.6913467363264796,0.623564807694282,7277,1
R-HSA-380287,Centrosome maturation,1/112,82/11091,0.5662720782634385,0.6913467363264796,0.623564807694282,7277,1
R-HSA-74752,Signaling by Insulin receptor,1/112,82/11091,0.5662720782634385,0.6913467363264796,0.623564807694282,2246,1
R-HSA-1168372,Downstream signaling events of B Cell Receptor (BCR),1/112,83/11091,0.5706846068522742,0.6933680126731737,0.6253879113992631,84433,1
R-HSA-195253,Degradation of beta-catenin by the destruction complex,1/112,83/11091,0.5706846068522742,0.6933680126731737,0.6253879113992631,51176,1
R-HSA-2990846,SUMOylation,2/112,189/11091,0.5721850409492875,0.6935158448132328,0.6255212495856509,8204/1029,2
R-HSA-2029480,Fcgamma receptor (FCGR) dependent phagocytosis,1/112,86/11091,0.5836570024526124,0.7057198851770771,0.6365287653266091,6850,1
R-HSA-2565942,Regulation of PLK1 Activity at G2/M Transition,1/112,88/11091,0.5920886661699329,0.7112441490250894,0.6415114120117474,7277,1
R-HSA-418346,Platelet homeostasis,1/112,88/11091,0.5920886661699329,0.7112441490250894,0.6415114120117474,5136,1
R-HSA-190236,Signaling by FGFR,1/112,89/11091,0.5962408128016667,0.7112441490250894,0.6415114120117474,2246,1
R-HSA-5687128,MAPK6/MAPK4 signaling,1/112,89/11091,0.5962408128016667,0.7112441490250894,0.6415114120117474,2308,1
R-HSA-9616222,Transcriptional regulation of granulopoiesis,1/112,89/11091,0.5962408128016667,0.7112441490250894,0.6415114120117474,51176,1
R-HSA-446203,Asparagine N-linked glycosylation,3/112,304/11091,0.5967098029594189,0.7112441490250894,0.6415114120117474,7277/149111/9331,3
R-HSA-201722,Formation of the beta-catenin:TCF transactivating complex,1/112,90/11091,0.6003510681158108,0.7122089322222945,0.6423816046621511,51176,1
R-HSA-390466,Chaperonin-mediated protein folding,1/112,90/11091,0.6003510681158108,0.7122089322222945,0.6423816046621511,7277,1
R-HSA-5617833,Cilium Assembly,2/112,201/11091,0.6058797592741267,0.7167426950794965,0.6464708623611237,7277/57576,2
R-HSA-111885,Opioid Signalling,1/112,92/11091,0.6084475761410437,0.7167426950794965,0.6464708623611237,5136,1
R-HSA-2682334,EPH-Ephrin signaling,1/112,92/11091,0.6084475761410437,0.7167426950794965,0.6464708623611237,2902,1
R-HSA-380320,Recruitment of NuMA to mitotic centrosomes,1/112,94/11091,0.6163814916824834,0.722703707030977,0.6518474369160847,7277,1
R-HSA-8936459,RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function,1/112,94/11091,0.6163814916824834,0.722703707030977,0.6518474369160847,8013,1
R-HSA-6803157,Antimicrobial peptides,1/112,95/11091,0.6202884911306568,0.7255932814853961,0.6544537079003993,1113,1
R-HSA-391251,Protein folding,1/112,96/11091,0.6241560510609374,0.7284234192196092,0.6570063695378289,7277,1
R-HSA-9759194,Nuclear events mediated by NFE2L2,1/112,97/11091,0.6279845660478565,0.7311949924122032,0.6595062084956776,1029,1
R-HSA-202424,Downstream TCR signaling,1/112,98/11091,0.631774426753936,0.7315093547916841,0.6597897497440951,84433,1
R-HSA-5620912,Anchoring of the basal body to the plasma membrane,1/112,98/11091,0.631774426753936,0.7315093547916841,0.6597897497440951,7277,1
R-HSA-1483257,Phospholipid metabolism,2/112,212/11091,0.6349890119471917,0.7315093547916841,0.6597897497440951,43/1103,2
R-HSA-6811434,COPI-dependent Golgi-to-ER retrograde traffic,1/112,99/11091,0.6355260199681232,0.7315093547916841,0.6597897497440951,7277,1
R-HSA-9679191,Potential therapeutics for SARS,1/112,99/11091,0.6355260199681232,0.7315093547916841,0.6597897497440951,6850,1
R-HSA-6807878,COPI-mediated anterograde transport,1/112,101/11091,0.6429159319367141,0.7383258305117973,0.6659379155604993,7277,1
R-HSA-9645723,Diseases of programmed cell death,1/112,104/11091,0.6537232448879854,0.7490268614547988,0.6755897819127723,1029,1
R-HSA-211859,Biological oxidations,2/112,222/11091,0.6599864048715807,0.7502391209819664,0.6766831874923668,4128/4129,2
R-HSA-8939211,ESR-mediated signaling,2/112,222/11091,0.6599864048715807,0.7502391209819664,0.6766831874923668,6387/8204,2
R-HSA-373076,Class A/1 (Rhodopsin-like receptors),3/112,334/11091,0.6604296938140108,0.7502391209819664,0.6766831874923668,718/6387/7852,3
R-HSA-428157,Sphingolipid metabolism,1/112,106/11091,0.6607473769284515,0.7502391209819664,0.6766831874923668,9331,1
R-HSA-194138,Signaling by VEGF,1/112,108/11091,0.6676302728694269,0.7563469082282022,0.6821921470050332,7424,1
R-HSA-2559582,Senescence-Associated Secretory Phenotype (SASP),1/112,110/11091,0.6743747475090076,0.7605616547018629,0.6859936657455328,1029,1
R-HSA-9748784,Drug ADME,1/112,110/11091,0.6743747475090076,0.7605616547018629,0.6859936657455328,1645,1
R-HSA-5610787,Hedgehog 'off' state,1/112,113/11091,0.6842379403434561,0.7699590245923006,0.6944696863017298,7277,1
R-HSA-446728,Cell junction organization,1/112,115/11091,0.6906483142805335,0.7754377278640812,0.699411239320747,3914,1
R-HSA-9610379,HCMV Late Events,1/112,116/11091,0.6938049641348136,0.7772469865474638,0.7010431122778212,1052,1
R-HSA-9648025,EML4 and NUDC in mitotic spindle formation,1/112,117/11091,0.6969296879632331,0.7790125178789027,0.7026355450576688,7277,1
R-HSA-8878166,Transcriptional regulation by RUNX2,1/112,120/11091,0.7061154875968465,0.787530133616882,0.7103180654784476,25937,1
R-HSA-2132295,MHC class II antigen presentation,1/112,123/11091,0.7150252845460783,0.7957029162094631,0.7176895613399156,7277,1
R-HSA-71291,Metabolism of amino acids and derivatives,3/112,367/11091,0.7218787484441008,0.8015563144975335,0.7229690730322005,445/1373/1735,3
R-HSA-9755511,KEAP1-NFE2L2 pathway,1/112,126/11091,0.723667299291214,0.801772360227931,0.7231639369221265,1029,1
R-HSA-2500257,Resolution of Sister Chromatid Cohesion,1/112,127/11091,0.7264898494489325,0.8031305368633254,0.7243889534123537,7277,1
R-HSA-6809371,Formation of the cornified envelope,1/112,129/11091,0.732049509633222,0.8075019810208568,0.7283318066757126,11005,1
R-HSA-198933,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,1/112,133/11091,0.7428349984572773,0.8158209699214203,0.7358351742934648,718,1
R-HSA-8856688,Golgi-to-ER retrograde transport,1/112,133/11091,0.7428349984572773,0.8158209699214203,0.7358351742934648,7277,1
R-HSA-9609690,HCMV Early Events,1/112,135/11091,0.748065257311729,0.8197752166183,0.7394017335199065,7277,1
R-HSA-1632852,Macroautophagy,1/112,136/11091,0.7506407128777279,0.8208093012554286,0.7403344330670497,7277,1
R-HSA-202733,Cell surface interactions at the vascular wall,1/112,137/11091,0.7531900730016617,0.8218104267241558,0.7412374048720544,57126,1
R-HSA-913531,Interferon Signaling,2/112,269/11091,0.759631342442697,0.8264020446432069,0.7453788453305893,7277/3434,2
R-HSA-5663220,RHO GTPases Activate Formins,1/112,140/11091,0.7606841882103474,0.8264020446432069,0.7453788453305893,7277,1
R-HSA-3858494,Beta-catenin independent WNT signaling,1/112,146/11091,0.7750024087024531,0.8401426973649437,0.757772318853805,51176,1
R-HSA-162587,HIV Life Cycle,1/112,149/11091,0.7818397766125165,0.8439171837684458,0.7611767420826623,7852,1
R-HSA-5358351,Signaling by Hedgehog,1/112,149/11091,0.7818397766125165,0.8439171837684458,0.7611767420826623,7277,1
R-HSA-9612973,Autophagy,1/112,151/11091,0.7862832055768177,0.8468960436940884,0.7638635446942599,7277,1
R-HSA-1500931,Cell-Cell communication,1/112,153/11091,0.7906369236941511,0.8479538861794413,0.7648176727913345,3914,1
R-HSA-446652,Interleukin-1 family signaling,1/112,153/11091,0.7906369236941511,0.8479538861794413,0.7648176727913345,90865,1
R-HSA-1474165,Reproduction,1/112,154/11091,0.7927807035941561,0.8484440295911926,0.7652597609161954,7852,1
R-HSA-1852241,Organelle biogenesis and maintenance,2/112,296/11091,0.8047483714851803,0.8580775718590934,0.7739487987261049,7277/57576,2
R-HSA-5633007,Regulation of TP53 Activity,1/112,160/11091,0.8051940634542587,0.8580775718590934,0.7739487987261049,1029,1
R-HSA-983231,Factors involved in megakaryocyte development and platelet production,1/112,168/11091,0.8206057669234427,0.87265264431816425,0.7870948827061395,7277,1
R-HSA-109581,Apoptosis,1/112,180/11091,0.8414856889792975,0.8929689906257103,0.8054193469910665,1029,1
R-HSA-2467813,Separation of Sister Chromatids,1/112,190/11091,0.8570317030340228,0.9075514665812915,0.8185721086042411,7277,1
R-HSA-69275,G2/M Transition,1/112,197/11091,0.867005087054466,0.9152135151887345,0.825482944535617,7277,1
R-HSA-6798695,Neutrophil degranulation,3/112,480/11091,0.8689241604659085,0.9152135151887345,0.825482944535617,718/5788/57126,3
R-HSA-453274,Mitotic G2-G2/M phases,1/112,199/11091,0.8697257659248808,0.9152135151887345,0.825482944535617,7277,1
R-HSA-6811442,Intra-Golgi and retrograde Golgi-to-ER traffic,1/112,202/11091,0.8737036876446751,0.916929935944258,0.8270310817034114,7277,1
R-HSA-9705683,SARS-CoV-2-host interactions,1/112,203/11091,0.875002722173447,0.916929935944258,0.8270310817034114,2697,1
R-HSA-68877,Mitotic Prometaphase,1/112,205/11091,0.8775611951983424,0.9176991292822582,0.827724860773576,7277,1
R-HSA-3700989,Transcriptional Regulation by TP53,2/112,362/11091,0.8850385065036154,0.9226114035563293,0.8321555193738158,3486/1029,2
R-HSA-5357801,Programmed Cell Death,1/112,213/11091,0.8872863292257583,0.9226114035563293,0.8321555193738158,1029,1
R-HSA-6805567,Keratinization,1/112,215/11091,0.8895954885185282,0.9226114035563293,0.8321555193738158,11005,1
R-HSA-9711123,Cellular response to chemical stress,1/112,215/11091,0.8895954885185282,0.9226114035563293,0.8321555193738158,1029,1
R-HSA-5689880,Ub-specific processing proteases,1/112,219/11091,0.8940740695176836,0.92534826536501,0.8346240501670384,90865,1
R-HSA-162906,HIV Infection,1/112,231/11091,0.9064575464606002,0.9315554687106673,0.8402226786947735,7852,1
R-HSA-201681,TCF dependent signaling in response to WNT,1/112,232/11091,0.9074222568470101,0.9315554687106673,0.8402226786947735,51176,1
R-HSA-157118,Signaling by NOTCH,1/112,235/11091,0.9102576193647715,0.9315554687106673,0.8402226786947735,8788,1
R-HSA-68882,Mitotic Anaphase,1/112,235/11091,0.9102576193647715,0.9315554687106673,0.8402226786947735,7277,1
R-HSA-2555396,Mitotic Metaphase and Anaphase,1/112,236/11091,0.9111834803293206,0.9315554687106673,0.8402226786947735,7277,1
R-HSA-8878171,Transcriptional regulation by RUNX1,1/112,236/11091,0.9111834803293206,0.9315554687106673,0.8402226786947735,8013,1
R-HSA-9679506,SARS-CoV Infections,2/112,414/11091,0.925603176092724,0.9443780883866941,0.8517881261790627,2697/6850,2
R-HSA-9012999,RHO GTPase cycle,2/112,449/11091,0.9449046563239207,0.9621195184836683,0.8677901275849347,2697/10409,2
R-HSA-5663202,Diseases of signal transduction by growth factor receptors and second messengers,2/112,459/11091,0.9494857508046386,0.9634550911306349,0.8689947562567828,2308/2246,2
R-HSA-69620,Cell Cycle Checkpoints,1/112,292/11091,0.9503852185783722,0.9634550911306349,0.8689947562567828,1029,1
R-HSA-5688426,Deubiquitination,1/112,297/11091,0.9529057150041116,0.9634550911306349,0.8689947562567828,90865,1
R-HSA-9694516,SARS-CoV-2 Infection,1/112,299/11091,0.9538780027496148,0.9634550911306349,0.8689947562567828,2697,1
R-HSA-983168,Antigen processing: Ubiquitination & Proteasome degradation,1/112,309/11091,0.9584489250311607,0.9661318823460397,0.8714091059770706,84676,1
R-HSA-195258,RHO GTPase Effectors,1/112,326/11091,0.9652118554126295,0.9708448237096321,0.8756599749269675,7277,1
R-HSA-195721,Signaling by WNT,1/112,331/11091,0.9669846057227149,0.9708448237096321,0.8756599749269675,51176,1
R-HSA-983169,Class I MHC mediated antigen processing & presentation,1/112,381/11091,0.9804573537675645,0.9824104560659063,0.8860916743003151,84676,1
R-HSA-68886,M Phase,1/112,417/11091,0.986623182966555,0.986623182966555,0.889891371473444,7277,1
